Synergistic anti-biofilm activity of
exebacase and rifampin, vancomycin or daptomycin
against Staphylococcus epidermidis strains
responsible for bone and joint infections
Aubin Souche, Camille Kolenda, Raymond Schuch, Tristan Ferry,
Frédéric Laurent, Jérôme Josse
CIRI - Centre International de Recherche en Infectiologie
Equipe Pathogénie des Staphylocoques
INSERM U1111 - CNRS UMR5308 - ENS Lyon - Université de Lyon
Conflict of interest
1
- This study was founded by ContraFect Corporation
- ContraFect Corporation have no impact on study design, results and interpretation
BJI epidemiolgy
2 | Bone and Joint Infections | M & M | Bactericidal synergies ? | Anti-biomass synergies ? | Conclusion |
- Prevalence 70/100 000 inhbts
- Morbidity 40% - Mortality 5%
- Increasing number
BJI
Laurent et al. 2018
BJI epidemiolgy
2 | Bone and Joint Infections | M & M | Bactericidal synergies ? | Anti-biomass synergies ? | Conclusion |
- Prevalence 70/100 000 inhbts
- Morbidity 40% - Mortality 5%
- Increasing number
BJI
S. aureus | > |
30-70% |
S. epidermidis
17-48%
Laurent et al. 2018
BJI epidemiolgy
2 | Bone and Joint Infections | M & M | Bactericidal synergies ? | Anti-biomass synergies ? | Conclusion |
- Prevalence 70/100 000 inhbts
- Morbidity 40% - Mortality 5%
- Increasing number
BJI
S. aureus | > |
30% = PJIff
S. epidermidis
Laurent et al. 2018
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
ContraFect Corporation published this content on 19 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 July 2021 15:03:07 UTC.